CRNX Crinetics Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRNX

Price (delayed)

$33.25

Market cap

$2.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.63

Enterprise value

$2.13B

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, ...

Highlights
CRNX's equity has surged by 116% since the previous quarter and by 56% year-on-year
The quick ratio has soared by 69% QoQ but it has decreased by 9% YoY
CRNX's net income is down by 33% year-on-year and by 8% since the previous quarter
The company's EPS fell by 21% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.crinetics.com
Peers: OMGA

Key stats

What are the main financial stats of CRNX
Market
Shares outstanding
66.8M
Market cap
$2.22B
Enterprise value
$2.13B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.32
Price to sales (P/S)
400.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
450.9
Earnings
Revenue
$4.72M
EBIT
-$199.42M
EBITDA
-$197.77M
Free cash flow
-$167.03M
Per share
EPS
-$3.63
Free cash flow per share
-$2.94
Book value per share
$10.02
Revenue per share
$0.08
TBVPS
$11.29
Balance sheet
Total assets
$641.54M
Total liabilities
$93.79M
Debt
$52.17M
Equity
$547.75M
Working capital
$535.3M
Liquidity
Debt to equity
0.1
Current ratio
14.23
Quick ratio
13.74
Net debt/EBITDA
0.46
Margins
EBITDA margin
-4,188.4%
Gross margin
100%
Net margin
-4,223.3%
Operating margin
-4,394.5%
Efficiency
Return on assets
-49.8%
Return on equity
-57%
Return on invested capital
-62.7%
Return on capital employed
-33.2%
Return on sales
-4,223.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
-0.75%
1 week
3.81%
1 month
9.05%
1 year
83.3%
YTD
81.69%
QTD
11.8%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$4.72M
Gross profit
$4.72M
Operating income
-$207.51M
Net income
-$199.42M
Gross margin
100%
Net margin
-4,223.3%
The operating margin has contracted by 48% YoY and by 11% from the previous quarter
The net margin has declined by 44% year-on-year and by 11% since the previous quarter
CRNX's operating income is down by 37% YoY and by 8% from the previous quarter
CRNX's net income is down by 33% year-on-year and by 8% since the previous quarter

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.32
P/S
400.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
450.9
The company's EPS fell by 21% YoY and by 7% QoQ
CRNX's equity has surged by 116% since the previous quarter and by 56% year-on-year
CRNX's P/B is 4.6% below its 5-year quarterly average of 3.5
The P/S is 67% above the last 4 quarters average of 240.7 but 45% below the 5-year quarterly average of 734.7
The revenue is down by 8% year-on-year and by 2.3% since the previous quarter

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales fell by 44% YoY and by 11% QoQ
The company's return on equity fell by 31% YoY but it rose by 7% QoQ
The ROA has decreased by 24% YoY but it has increased by 9% from the previous quarter
The return on invested capital rose by 7% since the previous quarter

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The total liabilities has soared by 180% YoY and by 140% from the previous quarter
The total assets has surged by 119% since the previous quarter and by 67% year-on-year
The debt is 90% smaller than the equity
CRNX's equity has surged by 116% since the previous quarter and by 56% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.